ArticleJournal of translational medicine2025
Machine learning models for predicting metabolic dysfunction-associated steatotic liver disease prevalence using basic demographic and clinical characteristics.
Article in Journal of translational medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 28 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
28 citing papers in PubMed.
- Habitat imaging based on enhanced CT for predicting occult central lymph node metastasis in papillary thyroid carcinoma.European radiology · 2026Article
- Enhanced prediction of coronary heart disease risk in diabetic patients via Machine learning incorporating multiple inflammatory and metabolic indices: A study with Dual-Cohort validation.International journal of cardiology. Heart & vasculature · 2026Article
- Development and Validation of an Explainable Machine Learning Model to Assess the Prevalence Probability of Gastrointestinal Heat Retention Syndrome in Children: Cross-Sectional Study.Journal of medical Internet research · 2026Article
- Review
- Interpretable Machine Learning for Predicting Metabolic Syndrome-Kidney Stone Disease Comorbidity: The Role of Dietary Micronutrients.Food science & nutrition · 2026Article
- Development and validation of an explainable machine learning model using routine laboratory biomarkers for identifying prevalent MASLD: Evidence from two observational studies.Clinical and experimental medicine · 2026Article
- Artificial intelligence predicts sex-specific risk of metabolic dysfunction-associated steatotic liver disease.Biology of sex differences · 2026Article
- Article
- MASLD biomarker discovery: evaluating lipidomics techniques across disease progression.Molecular biology reports · 2026Review
- Applications of Artificial Intelligence and Smart Devices in Metabolic Dysfunction-associated Steatotic Liver Disease.Journal of clinical and translational hepatology · 2026Article
- Artificial intelligence in metabolic dysfunction-associated steatotic liver disease: Transforming diagnosis and therapeutic approaches.World journal of gastroenterology · 2026Review
- Risk Scores for Stratifying Hepatocellular Carcinoma and Optimizing Surveillance Strategies.Cancers · 2026Review
- Machine learning-based multicenter prediction of postoperative sepsis in emergency colon cancer: role of surgical approach and inflammatory markers.Frontiers in oncology · 2026Article
- Identification of cardiovascular disease in patients with kidney stone disease using explainable machine learning.Frontiers in cardiovascular medicine · 2026Article
- Association between UMAP-identified body composition phenotypes and metabolic dysfunction-associated steatotic liver disease in the general population of China.Frontiers in nutrition · 2026Article
- Machine Learning Models to Predict Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) With Simple Anthropometric and Biochemical Variables: A Cross-Sectional Study in US Population.International journal of hepatology · 2026Article
- Predicting In-Hospital Mortality in Pediatric Sepsis: Machine Learning Development and Multicenter Validation.Journal of inflammation research · 2026Article
- Machine learning-based identification of targeted metabolomic biomarkers for early diagnosis and fibrosis-stage discrimination in metabolic dysfunction-associated steatotic liver disease.Frontiers in nutrition · 2026Article
- Development of a Neural Network to Detect Hepatic Steatosis in Metabolic Dysfunction-Associated Steatotic Liver Disease.Gastro hep advances · 2026Article
- An interpretable machine learning model for predicting metabolic dysfunction-associated steatotic liver disease in patients with type 2 diabetes.Diabetes, obesity & metabolism · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors.
Funding
Abstract
backgroundMetabolic dysfunction-associated steatotic liver disease (MASLD) is a global health concern that necessitates early screening and timely intervention to improve prognosis. The current diagnostic protocols for MASLD involve complex procedures in specialised medical centres. This study aimed to explore the feasibility of utilising machine learning models to accurately screen for MASLD in large populations based on a combination of essential demographic and clinical characteristics.
methodsA total of 10,007 outpatients who underwent transient elastography at the First Affiliated Hospital of Gannan Medical University were enrolled to form a derivation cohort. Using eight demographic and clinical characteristics (age, educational level, height, weight, waist and hip circumference, and history of hypertension and diabetes), we built predictive models for MASLD (classified as none or mild: controlled attenuation parameter (CAP) ≤ 269 dB/m; moderate: 269-296 dB/m; severe: CAP > 296 dB/m) employing 10 machine learning algorithms: logistic regression (LR), multilayer perceptron (MLP), extreme gradient boosting (XGBoost), bootstrap aggregating, decision tree, K-nearest neighbours, light gradient boosting machine, naive Bayes, random forest, and support vector machine. These models were externally validated using the National Health and Nutrition Examination Survey (NHANES) 2017-2023 datasets.
resultsIn the hospital outpatient cohort, machine learning algorithms demonstrated robust predictive capabilities. Notably, LR achieved the highest accuracy (ACC) of 0.711 in the test cohort and 0.728 in the validation cohort, coupled with robust areas under the receiver operating characteristic curve (AUC) values of 0.798 and 0.806, respectively. Similarly, MLP and XGBoost showed promising results, with MLP achieving an ACC of 0.735 in the test cohort, and XGBoost registering an AUC of 0.798. External validation using the NHANES datasets yielded consistent AUC results, with LR (0.831), MLP (0.823), and XGBoost (0.784) performing robustly.
conclusionsThis study demonstrated that machine learning models constructed using a combination of essential demographic and clinical characteristics can accurately screen for MASLD in the general population. This approach significantly enhances the feasibility, accessibility, and compliance of MASLD screening and provides an effective tool for large-scale health assessments and early intervention strategies.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.